Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins ‘Fast Money’ to talk Zepbound’s recent trial results and what it means for Eli Lilly’s future growth.
Trending
- On Christmas Day, Pope Francis calls for talks to end Ukraine war
- Japan’s budget to hit record, but with reduced new bond issuance, Reuters reports
- Who had it good — and who had it bad — in 2024
- Singapore manufacturing data on deck
- One of the best experiences I’ve had as a parent
- His dad’s illness drew Andrew Wiggins away from basketball. Now the Warrior is rediscovering his joy
- I interviewed leading longevity experts in 2024: 3 things I learned
- Most interesting NBA awards: An unknown Rookie of the Year? Wide-open Most Improved race?
Eli Lilly Chief Scientific Officer explains Zepbound’s weight loss advantage
